NEW YORK (GenomeWeb News) – WaferGen Biosystems said in a filing with the US Securities and Exchange Commission that it would not be able to file its third-quarter earnings document with the agency by Nov. 15 as required. The company said that it would miss the deadline because management has "devoted considerable time and internal accounting resources to completing work" on a regulatory filing associated with the potential sale of 112 million shares of its common stock by its shareholders.
WaferGen said it intends to file its Form 10-Q on or before Nov. 21.
Modern Mobility Aids has finished its due diligence for its proposed purchase of Lumigene Technologies, announced in August, and expects to close the deal on Nov. 30.
Clongen Laboratories has split its business into two distinct units, the Clinical Diagnostics Division and the Contract Research Division. Using Real-time PCR, the Clinical Diagnostics Division focuses on tick-borne illness testing, but offers other assays as well. The CRO business offers assays to pharmaceutical, biotechnology, government, and academic institutions.
Pandora Genomics was one of two winners of the Florida IDEA Grants Program announced this week. The grants are for up to $50,000 each. Based in Orlando, Fla., Pandora develops DNA-based tests to help physicians in making medication decisions. The other recipient of the grant program is online data mining company Rillip.
Toray Industries announced a competition for use of 3D-Gene DNA microarray technology in order to encourage research. The award this year focuses on research related to microRNA expression, in particular from blood samples and FFPE samples. The grant is for $2,000. Winners also receive free DNA microarray analyses with 3D-Gene matched to the research plan. The due date for applying is Nov. 30. Further details are available here.